83-5969-41　VEGFR2, Ramucirumab Biosimilar 5mg　592141

特徴

• Research grade Ramucirumab biosimilar uses the same protein sequences as the therapeutic antibody ramucirumab.
• Ramucirumab, a fully human IgG1 monoclonal antibody and a direct VEGFR2 antagonist, binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D).
• These ligands are secreted by solid tumors to promote angiogenesis (formation of new blood vessels from pre-existing ones) and enhance tumor blood supply.
• Binding of ramucirumab to VEGFR2 leads to inhibition of VEGF-mediated tumor angiogenesis.
• Kinase insert domain receptor (KDR, a type IV receptor tyrosine kinase, CD309, cluster of differentiation 309, Flk1, Fetal Liver Kinase 1) is the human gene encoding vascular endothelial growth factor receptor 2 (VEGFR-2), which is a VEGF receptor.
• The Q472H germline KDR genetic variant affects VEGFR-2 phosphorylation and has been found to associate with microvessel density in NSCLC.
• Applications:Suitable for use in ELISA, Neutralization, Functional Assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Ramucirumab.
• Other applications not tested.
• Recommended Dilution:Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4℃ for short-term only.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20℃.
• Aliquots are stable for 12 months after receipt.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.